What the trial was testing
The trial enrolled 274 patients with atopic dermatitis. The study was sponsored by Kyowa Kirin and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
About 50-60% reduction in eczema severity vs. 15% in the comparison group.
The Lancet · 2023 · NCT03703102
These findings — that in eczema severity at 16 weeks on rocatinlimab in moderate-to-severe atopic dermatitis — were published in the The Lancet and represent the headline result of the study.
Researchers tracked outcomes across 274 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with atopic dermatitis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Rocatinlimab is still in development and not yet FDA-approved as of early 2026. Several biologics for moderate-to-severe atopic dermatitis are FDA-approved and available now, including dupilumab (Dupixent), tralokinumab (Adbry), and lebrikizumab (Ebglyss). Ask a dermatologist about approved options or open trials.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open atopic dermatitis trials
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
National Register of Moderate and Severe Adult Atopic Dermatitis
Collect clinical history and treatment data of AD in adulthood;